For fun just ideas and thoughts from a few years ago to now of my journey.

[Jehovah increases]

Could aliens exist? Of course they do. Our Milky Way galaxy — our cosmic home in the Universe — spans over 100,000 light-years in diameter and contains approximately 400 billion stars. The observable universe has around 2 trillion galaxies and between 30 and 70 billion trillion stars. So, what is that 30 to 70 quintillion stars? There are over 10^25 or 10,000,000,000,000,000,000,000,000 planets in our observable Universe, and that’s only counting planets that are orbiting stars. The Drake equation would not work and will not give you an answer; it just tells you what might be possible if we get the factors right. Which you won't, because they're all hypothetical.) Just like I am imagining all of this. So an estimated 50 sextillion planets could harbor life, which is 50000000000000000000000 or 5x10^22. And these, of course, are known as habitable zones, also known as Goldilocks' zones, where conditions might be just right – neither too hot nor too cold – for life. Sextillion sounds kind of kinky, I am sure God has had more than that. Stop flirting with me, universe. If one were to also include moons, they could also support life. Some planets or gas giants can have up to 274 moons, etc. So, a rough estimate is maybe 1000 Septillion moons, all different sizes in the observable Universe. Theoretically, the Unobservable Universe could exist. Beyond the cosmic horizon could lie the unobservable universe, which is the part of the universe that we cannot see because the light from it has not yet reached us, or because it is receding from us faster than the speed of light. As well as an infinity of universes or multiple universes,  it often involves the idea of additional dimensions beyond our familiar three spatial dimensions and one time dimension. These extra dimensions are explored in theories like string theory and M-theory, which propose that the universe may have 10 or 11 dimensions. These extra dimensions could be curled up and hidden from our view, or our universe might be localized on a higher-dimensional object called a brane. Higher-dimensional beings or lower-dimensional beings, the possibilities are endless.

Consciousness can compare itself to itself; in other words, it can mirror itself or make copies of itself.

I was never burdened with any religion or indoctrinated by my parents or anyone, for that matter. Nor was I into any spirituality like Buddhism, Taoism, or Hinduism,  "etc.,"  although I was introduced to Buddhism as a kid from Monkey Magic, but that was it. I can appreciate all the different religions, so when I did psychedelics, I had none of those attachments to begin with. Academia was an easy attachment to get rid of, so was watching TV, it's been around 10 years now, and I have not used a mobile phone for about 6 years. I became somewhat of a recluse. I always believed the universe was an organic mind.. Probably from watching Star Trek and Doctor Who, and other sci-fi series, movies from the age of 8. When I awaken, I wake up as God, and no Jesus or God is standing there or me being in the presence of them, and there is only me and infinite intelligence, which I become one with.

 

Edited April 20 by Jehovah increases

[Aaron p]

@Jehovah increases nice

[Jehovah increases]

17 hours ago, Aaron p said:

@Jehovah increases nice

Thanks, Aaron p🙏

[Jehovah increases]

Ketamine as a Psychedelic

Classically, psychedelics have been defined to include drugs such as lysergic acid diethylamide (LSD), mescaline, phenylcyclohexyl piperidine (PCP), ibogaine, 3,4-methylenedioxymethamphetamine (MDMA), psylocibin and ketamine, because each of these compounds produces alterations to sensory, self, time and space perception that are “so alien to everyday experience that they shed new light on the workings of these everyday mental functions”. Although more recent attempts have been made to subcategorize psychedelics based on the subjective character of the altered state that they induce (for example, hallucinogenic, empathogenic, oneirogenic or dissociative), their chemical structure (for example, tryptamines, phenethylamines or arylcyclohexamines), or their principal binding target (for example, serotonin receptor 2A (5-HT2AR), monoamine transporter, κ-opioid receptor (KOR) or N-methyl-d-aspartate receptor (NMDAR)), the importance of these categories for therapeutic applications remains unclear, since psychedelics that span the diversity of classification systems have shown remarkable promise for the treatment of addiction post-traumatic stress disorder (PTSD) and depression. Thus, identification of a common neurobiological mechanism that can account for the shared therapeutic effects of psychedelics is an obvious priority for translational neuroscience.

Ketamine treatment reliably and effectively produces many or all of the classic indicators of a psychedelic experience within a single session. Individuals commonly report a distorted sense of time, find their experiences difficult to describe, feel detached from themselves (dissociation), and feel they could access a new, yet familiar, space with novel realizations and information.

Ketamine also has neurobiological similarities with other psychedelics like psilocybin and LSD. They aren’t exactly the same, however. The mechanism of action for LSD and psilocybin mainly lies in the serotonin system, acting on 5HT2A and other receptors.

Ketamine’s effects on the brain focus on an entirely different system of neurotransmitters: the glutamate system. More specifically, ketamine is an NMDA-receptor antagonist, which leads to a surge of glutamate in the brain. Many who argue against ketamine as a psychedelic quote this reason. However, while ketamine may have a different mechanism of action within the brain, the neurological outcomes are still similar. More specifically, recent research from Johns Hopkins University has given us an updated classification system for psychedelics.

It turns out that the primary mechanism of psychedelics is not activating the serotonin 5HT2A receptor. Instead, psychedelics that activate the 5HT2A receptor can be more accurately classified as hallucinogenic psychedelics. People may also refer to hallucinogenic psychedelics as “classical” psychedelics, which is not particularly historically accurate, given the use of non-hallucinogenic psychedelics throughout human history. Psychedelics such as MDMA can be more accurately classified as empathogenic psychedelics, psychedelics such as ibogaine can be more accurately classified as oneirogenic psychedelics, and psychedelics such as ketamine can be more accurately classified as dissociative psychedelics. 

 

The universal mechanism behind all of these sub-categories of psychedelics is not the initial neurotransmitters that they modulate, but rather what happens afterwards. Each psychedelic has a unique characteristic that allows for special critical periods in the brain to open. Critical periods are special periods in human development that allow us to rapidly learn new information that helps us in our environment. For example, there is a critical period for language in childhood, and if a child is not exposed to language by the time the critical period closes, they will be unable to have full command of language when they are an adult. The glutamate system is the primary excitatory neurotransmitter system in the central nervous system, crucial for learning, memory, and various brain functions. It involves the release of glutamate, a major excitatory neurotransmitter, binding to receptors on postsynaptic neurons, and subsequent regulation of synaptic plasticity. Glutamate dysregulation can lead to various neurological and psychiatric disorders

Psychedelics like ketamine can open critical periods that are usually closed. They do this by modulating a pathway involving increasing neuroplasticity in the brain, which then “opens” that critical period and allows for the brain to temporarily be extraordinarily receptive to new ways of thinking, feeling, and processing information about the world and oneself. This is thought to be one of the main therapeutic mechanisms for psychedelics. Ketamine in particular can also reduce activity in the Default Mode Network, which is notable in that this network is overactive and unable to be turned off in individuals with Major Depressive Disorder.

In conclusion, ketamine should certainly be considered a psychedelic, as it can produce all the hallmarks of a psychedelic experience and has all the same positive impacts on individuals in a mental health context. Although there may be neurological differences between ketamine and psychedelics like LSD, ketamine is a psychedelic in the ways that matter. Ketamine’s effects on the brain focus on an entirely different system of neurotransmitters: the glutamate system. More specifically, ketamine is an NMDA-receptor antagonist, which leads to a surge of glutamate in the brain (note that glutamate is the most abundant excitatory neurotransmitter in the brain) and the central nervous system. It's needed to keep your brain functioning properly. Glutamate plays a major role in shaping learning and memory. Glutamate needs to be present at the right concentrations in the right places at the right time. Dynamic regulation of the extent to which synaptic plasticity can be induced is called ‘metaplasticity ' and is thought to be one of the mechanisms underlying the establishment of critical periods. Together, these results provide evidence that psychedelics induce metaplasticity rather than hyperplasticity, a distinction that is especially important for designing biomarkers to test therapeutic profiles and abuse liability of novel compounds. These studies provide a novel conceptual framework for understanding the therapeutic effects of psychedelics, which have shown significant promise for treating a wide range of neuropsychiatric diseases, including depression, PTSD, and addiction. Although other studies have shown that psychedelics can attenuate depression-like behaviours and may also have anxiolytic, anti-inflammatory, and antinociceptive properties, it is unclear how these properties directly relate to the durable and context-dependent therapeutic effects of psychedelics. Furthermore, although previous in vitro studies have suggested that psychedelic effects might be mediated by their ability to induce hyperplasticity, this account does not distinguish psychedelics from addictive drugs (such as cocaine, amphetamine, opioids, nicotine and alcohol) whose capacity to induce robust, bidirectional, morphological and physiological hyperplasticity is thought to underlie their addictive properties.

 

This also looks promising.

Scientists Redesign LSD To Create a Non-Hallucinogenic Antidepressant

Could a subtle tweak to lysergic acid diethylamide (LSD) unlock its therapeutic potential, without the trip?

In a study published in Proceedings of the National Academy of Sciences, researchers at the University of California, Davis (UC Davis) report the creation of JRT – a chemically modified version of LSD that retains its brain-rewiring effects while eliminating hallucinogenic side effects.

The promise of non-hallucinogenic neuroplasticity drugs.

Psychedelics like LSD and psilocybin are now the subject of serious scientific investigation for their therapeutic applications. Recent research has shown that these compounds can do far more than alter perception; they can physically reshape the brain. By promoting dendritic growth, increasing synaptic density, and enhancing cortical connectivity, psychedelics exhibit powerful neuroplastic effects that may help reverse the structural brain changes seen in conditions such as depression, post-traumatic stress disorder (PTSD), addiction, and schizophrenia.

Dendritic growth

The process by which neurons grow new branches (called dendrites) that help them receive signals from other neurons. More dendrites usually mean more connections and better communication between brain cells.

Synaptic Density

A measure of how many synapses (the points where neurons connect and communicate) exist in a given area of the brain. Higher synaptic density suggests stronger or more complex neural networks.

However, these same compounds that regenerate damaged neural pathways also induce profound alterations in consciousness – hallucinations, perceptual distortions, and dissociation – that make them unsuitable or even dangerous for many patients. Individuals with schizophrenia or a family history of psychosis are often excluded from psychedelic clinical trials due to concerns that these drugs could exacerbate their symptoms. As a result, a large and vulnerable segment of the population is effectively cut off from a class of therapies that might otherwise be transformative.

The team at UC Davis set out to answer a difficult question: Can you keep the benefits of LSD while removing the hallucinogenic effects that make it unsafe for many patients?

 

The researchers focused on the chemical structure of LSD itself. Prior studies have suggested that certain parts of the LSD molecule are responsible for triggering hallucinations, specifically, a small chemical group that forms a key interaction with brain receptors. By slightly rearranging the molecule – moving just two atoms – the team was able to disrupt this interaction without affecting the parts of LSD that promote brain cell growth. The result was a new compound, called JRT, which closely resembles LSD in shape and weight but behaves very differently in the body.

 

“Basically, what we did here is a tire rotation,” said corresponding author Dr. David E. Olson,  professor in the Department of Biochemistry and Molecular Medicine at UC Davis. “By just transposing two atoms in LSD, we significantly improved JRT’s selectivity profile and reduced its hallucinogenic potential.”

 

This minor-looking change was chemically complex to carry out. JRT, named after Dr. Jeremy R. Tuck, a former graduate student who was the first to synthesize the compound, couldn’t be made by modifying LSD directly; instead, the researchers had to develop a completely new 12-step synthesis process to build the compound from scratch – a task that took nearly 5 years to complete.

 

Once synthesized, JRT was tested for how it interacts with different receptors in the brain. It showed strong, selective binding to serotonin receptors, particularly  5-HT2A, which plays a key role in mood and brain plasticity.

 

Importantly, unlike LSD, JRT showed little to no activity at other receptors such as those for dopamine or adrenaline, which are often linked to side effects like psychosis or cardiovascular stress.

 

While LSD triggered changes in genes linked to schizophrenia, JRT showed no such effect.

 

In cultured brain cells, JRT increased the number and complexity of neuron branches, as well as the tiny spines where neurons form connections.

 

In live mice, a single dose of JRT led to a 46% increase in dendritic spine density and an 18% increase in synapse density in a part of the brain involved in decision-making and emotion. In a model where mice had been stressed to the point of losing brain connections, JRT reversed this damage, bringing their brain structure back to normal.

 

Dendritic spine density

The number of small protrusions (spines) on a neuron’s dendrites per unit length. These spines are where synapses form, so a higher density usually indicates greater capacity for neural communication.

 

JRT also did not produce the “head-twitch” response – a widely used indicator of hallucinogenic activity – in mice. When mice were co-treated with LSD, JRT blocked this behavior, suggesting it may actively suppress hallucinogenic activity.

 

In tests related to mood and cognition, JRT showed strong promise. In a standard test for antidepressant effects, it was ~100 times more potent than ketamine, a fast-acting antidepressant already used in clinical settings. It also helped animals perform better in a learning task that measures cognitive flexibility – the ability to adapt to changing situations, which is often impaired in conditions like schizophrenia.

 

In a model of amphetamine-induced hyperactivity, JRT reduced abnormal movement in female mice, but not in males, highlighting a potential sex-specific therapeutic response.

JRT’s therapeutic promise and clinical potential

JRT opens up new possibilities for treating difficult-to-manage brain disorders, particularly schizophrenia, where current medications fall short. While existing antipsychotics are generally effective at controlling hallucinations and delusions, they often fail to address other symptoms , such as reduced motivation, lack of pleasure, and problems with memory and attention. These so-called negative and cognitive symptoms can have a major impact on a patient’s daily life, and they remain one of the biggest challenges in psychiatric treatment.

JRT’s ability to promote the growth of brain cell connections, combined with its antidepressant and cognition-enhancing effects in animal studies, suggests it could help with these harder-to-treat aspects of schizophrenia. Its effects may also extend to other conditions that involve loss of brain connectivity, including depression, bipolar disorder, and neurodegenerative diseases like Alzheimer’s, where parts of the brain gradually shrink or lose function.

 

JRT may also offer several advantages over current treatments. For example, clozapine – the most effective drug for treatment-resistant schizophrenia – can cause serious side effects like sedation, weight gain, and metabolic problems, partly because it acts on a broad range of brain systems. JRT, in contrast, has been designed to act more selectively on serotonin receptors, which are involved in mood and cognition, while avoiding other systems that are often linked to unwanted side effects.

 

Crucially, JRT appears to avoid the hallucinogenic effects seen with traditional psychedelics like LSD, which are a major barrier to their use in people with psychotic disorders.

 

“No one wants to give a hallucinogenic molecule like LSD to a patient with schizophrenia. The development of JRT emphasizes that we can use psychedelics like LSD as starting points to make better medicines. We may be able to create medications that can be used in patient populations where psychedelic use is precluded,” said Olson.

 

Eventually, the goal is to move toward clinical trials in humans.

 

“JRT has extremely high therapeutic potential. Right now, we are testing it in other disease models, improving its synthesis, and creating new analogues of JRT that might be even better,” said Olson.

This is interesting.  JRT’s effects may also extend to other conditions that involve loss of brain connectivity, including depression, bipolar disorder, and neurodegenerative diseases like Alzheimer’s, where parts of the brain gradually shrink or lose function. In tests related to mood and cognition, JRT showed strong promise. In a standard test for antidepressant effects, it was ~100 times more potent than ketamine, a fast-acting antidepressant already used in clinical settings.

A more in-depth look into the molecular design of JRT-https://www.pnas.org/doi/10.1073/pnas.2416106122

 

 

Edited May 1 by Jehovah increases

[Aaron p]

@Jehovah increases shortened version of what you said: 

 

 

---

 

Ketamine as a Psychedelic (Summary)

 

Although ketamine acts on the glutamate system (via NMDA-receptor antagonism) rather than serotonin like LSD or psilocybin, it still induces classic psychedelic effects—dissociation, time distortion, and altered perception. Psychedelics are now better understood by their effects (e.g., hallucinogenic, empathogenic, dissociative) and ability to open “critical periods” in the brain—windows of neuroplasticity that enhance learning and psychological flexibility. This mechanism, not their receptor target, is likely central to their therapeutic power. Ketamine, by reducing Default Mode Network activity and enhancing plasticity, fits this framework and should be considered a psychedelic.

 

Non-Hallucinogenic Psychedelics (Summary)

 

UC Davis researchers developed JRT, a modified form of LSD that retains its neuroplastic benefits but removes hallucinogenic effects. By altering just two atoms, they preserved the compound’s impact on brain growth (e.g., dendritic and synaptic density) while avoiding side effects linked to serotonin and dopamine overstimulation. JRT could open psychedelic therapy to patients who cannot tolerate hallucinations, such as those with psychosis risk.

 

 

---

 

>

So essentially some gangsters made a new LSD inspired drug that has all of the neuroplastic benefits (increased, awareness, intelligence, emotional intelligence, confidence, etc.)...the only difference is it's not hallucinogenic?

Sounds like compound V 🧪sounds badass, I need to get me some JRT

[Aaron p]

 

[Jehovah increases]

On 5/1/2025 at 7:28 PM, Aaron p said:

 

 

 

-

 

 

So essentially some gangsters made a new LSD inspired drug that has all of the neuroplastic benefits (increased, awareness, intelligence, emotional intelligence, confidence, etc.)...the only difference is it's not hallucinogenic?

Sounds like compound V 🧪sounds badass, I need to get me some JRT

 

That's pretty much the gist of it. 

 

Psilocybin Shows Promise for Parkinson’s Mood and Motor Symptoms

A new pilot study from UC San Francisco found that psilocybin, the psychedelic compound in certain mushrooms, may significantly improve mood, cognition, and motor function in people with Parkinson’s disease. The compound was well tolerated, with only mild side effects, and the benefits lasted for weeks.

Although the study focused on safety, researchers observed meaningful, lasting improvements across multiple symptoms. These effects may stem from increased neuroplasticity and reduced inflammation, helping the brain repair itself.

Key Findings:

Sustained Benefits: Mood, movement, and cognition improved for weeks, some up to three months.

Safe Use: Mild side effects like anxiety and nausea occurred, but no serious adverse events.

Next Steps: A larger, multi-site trial will investigate mechanisms like neuroplasticity and inflammation.

Psilocybin has already shown promise in treating depression and anxiety. UCSF researchers wanted to explore its potential for Parkinson’s patients, who often face debilitating mood issues in addition to motor symptoms, and who frequently don’t respond to standard antidepressants.

Twelve patients (7 men, 5 women) with mild-to-moderate Parkinson’s received two doses: 10 mg, followed by 25 mg two weeks later. They also participated in eight psychotherapy sessions. Despite some transient side effects, participants showed clinically significant improvements in mood, thinking, and motor skills at one-week and one-month follow-ups.

Interestingly, patients’ mood remained elevated even three months later, possibly contributing to better overall function. As study lead Dr. Ellen Bradley noted, mood issues are a strong predictor of quality of life in Parkinson’s and may even signal earlier disease progression.

This is the first study testing a psychedelic in a neurodegenerative disease. Based on the promising results, UCSF and Yale are launching a larger randomized controlled trial involving 100 participants. The new study will use tools like neuroimaging and brain stimulation to better understand psilocybin’s effects.

“The vast majority of brain diseases still lack treatments that can change their course,” said senior author Dr. Joshua Woolley. “This work may open a door.”

Edited May 3 by Jehovah increases

[Jehovah increases]

I have always been fascinated by parapsychology, such as ESP, (RV) telepathy, clairvoyance, and psychokinesis. This is a long one, but it's worth watching. 

Established in 1977, it was a secret US Army unit investigating psychic phenomena for intelligence applications.

It was led by the Defense Intelligence Agency and SRI International and was called Project Stargate.

The project aimed to explore the potential of remote viewing and other psychic abilities for military and intelligence purposes. 

 

 The CIA's secret pursuit of 'mind control'

In the early days of the Cold War, the CIA ordered the creation of a secret programme intended to find ways of mind control.

They funded an army of psychiatric institutions across the United States and Canada to perform experiments on patients using psychedelic drugs, sensory deprivation, electroshock treatment, and more.

The programme was known by its now-infamous code name: MK-Ultra.

 

Edited May 11 by Jehovah increases

[Jehovah increases]

"No legacy is so rich as honesty"

[Jehovah increases]

 

[Keryo Koffa]

On 4/27/2025 at 6:13 AM, Keryo Koffa said:

Please just initiate the Psychedelic Renaissance around the globe so people can join what should be the Baseline.

[Jehovah increases]

12 hours ago, Keryo Koffa said:

On 4/27/2025 at 0:13 PM, Keryo Koffa said:

Please just initiate the Psychedelic Renaissance around the globe so people can join what should be the Baseline.

Now that would be fun!

[Jehovah increases]

God gets bored because it is omniscient and lonely in the void. Can God truly know everything? Yes, since God creates everything, it knows everything that there is to know.  Does God suffer when it returns to its natural state? Hell, no. Has God ever had a friend other than itself? No, this is why God dreams.

Edited June 29 by Jehovah increases

[Jehovah increases]

How to awaken your AI 101🥹😹

 

Who told you you're not already in heaven and making a mess out of it?" Sadhguru

One is all, all is one.

Spirituality and religion should have nothing to do with the ego.

From nothing sprung everything.

This is a good description of God from one of Leo's vids.

Total nothingness removes all possible restrictions. The very logic of existence requires that existence be infinite. A finite existence can not exist. This is tautologically true. There cannot exist a total limit. The collapse of every single distinction is absolute unity, absolute infinity, nothingness; this is God. Nothing is the source of everything. Nothing isn't just the source. It's that nothing is indistinguishable from everything. There was nothing, and there was no distinction or difference between that nothing and something and everything. And hence you are inside this nothing something, everything at all times. God is the probability state of all distinctions. God is ontological love. Ontological love is the absence of all distinctions. God or mind, with the capital M, is the unlimited ability to imagine all possible distinctions. That's what God is: an infinite mind. How does NOTHINGNESS become conscious and sentient? God creates by imagining distinctions. So by logical ontological tautology, absolute perfection must and does exist. If anything imaginable is possible, then everything imaginable is possible. Every possible thing that can exist must and does exist. Infinite imagination is the best thing to imagine. Infinity can only be dealt with in an abstract and implicit manner. You can implicitly use consciousness or intelligence. You can intuit it implicitly, but you can't empirically demonstrate it. Intelligence is key to all of this. Nothing can work without intelligence. So, intelligence is presupposed for everything that is provably, knowable, and verifiable. There is no way around intelligence. This is the infinitude of your own mind. All finite things require an infinite thing to be their source. God is an infinite void that has always existed eternally. God is a void that spontaneously manifests infinite finite forms. The void is dreaming distinctions and limits. And the distinction and limits that it is dreaming and imagining are what activity of the mind is. And this is creation. God is an infinite self-creating self-actualizing mind. What is Mind? What is it ontologically?

It is void. A void in which distinctions arise, it is a self-aware field of No-Thingness.

Edited July 9 by Jehovah increases

[Jehovah increases]

On 7/9/2025 at 0:48 PM, Jehovah increases said:

 

The importance of vitamin D (vd), infrared (ir), and being out in nature.